A Phase I/Ib study of AZD9150 (ISIS-STAT3Rx) in patients with advanced/metastatic hepatocellular carcinoma

Study identifier:D5660C00001

ClinicalTrials.gov identifier:NCT01839604

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I/Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 in Patients with Advanced/Metastatic Hepatocellular Carcinoma

Medical condition

Advanced Adult Hepatocellular Carcinoma

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD9150

Sex

All

Actual Enrollment

58

Study type

Interventional

Age

18 Years - 150 Years

Date

Study Start Date: 01 May 2013
Primary Completion Date: 01 Feb 2015
Study Completion Date: 01 Feb 2015

Study design

Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 May 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Isis Pharmaceuticals, Inc.

Inclusion and exclusion criteria